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Background: Immunotherapy with T cells expressing
chimeric antigen receptors (CARs) has shown promise for
the immunotherapy of CD19+ malignancies in early clinical
studies. However, clinical efﬁcacy depends on signiﬁcant in
vivo expansion of adoptively transferred T cells, which can
be difﬁcult to achieve. Genetically modifying T cells with
bispeciﬁc T-cell engagers, which are able to recruit other T
cells locally, amplifying antitumor effects, could potentially
overcome this problem. Consistent and prolonged syn-
thesis of engagers by T cells should also be superior to the
intermittent direct infusion of the protein, both because
these molecules have short half-lives and do not accumu-
late at tumor sites. The goal of this project was to generate
T cells secreting CD19-speciﬁc T-cell engagers (CD19-ENG T
cells) and to evaluate their effector function in vitro and in
vivo.
Methods: A CD19-speciﬁc T-cell engager gene, consisting of
two single chain variable fragments speciﬁc for CD3
and CD19, was synthesized and subcloned into a SFG retro-
viral vector in front of an IRES and mOrange. CD19-ENG T
cells were generated by retroviral transduction and we
determined their effector function in coculture and cyto-
toxicity assays, and in the Ph+ ALL BV173/xenograft model.
Results: Post transduction 50-60% of T cells were positive for
transgene expression. In coculture assay CD19-ENG T cells
recognized CD19+ lymphoma (Daudi, Raji) and acute leuke-
mia (BV173) cells as judged by IFN-g and IL-2 secretion in
contrast to CD19- K562 cells. None of the targets were
recognized by non-transduced (NT) T cells or T cells secreting
engagers speciﬁc for an irrelevant antigen (EphA2-ENG T
cells). Antigen-dependent recognition was conﬁrmed in
standard cytotoxicity assays. In transwell assays containing
inserts that do not allow T-cell migration, only CD19-ENG
T cells redirected NT T cells in the bottom well to CD19-
positive tumor cells, demonstrating the ability of a diffusible
product from CD19-ENG T cells to redirect NT T cells to
CD19-positive tumor cells. To assess the anti-tumor activity
of CD19-ENG T cells in vivo we used BV173 cells that were
genetically modiﬁed with ﬁre ﬂy luciferase (ffLuc; ffLuc-
BV173) to allow for serial bioluminescence imaging. NSG
mice were injected iv with ffLuc-BV173 cells, and received an
iv dose of CD19-ENG or EphA2-ENG T cells and an ip dose of
IL2 on days 7, 14, and 21 post leukemia cell injection.
Untreated mice served as controls. CD19-ENG T cells had
potent anti-leukemia activity in contrast to EphA2-ENG T
cells resulting in a signiﬁcant survival advantage of treated
animals.
Conclusions: We have generated CD19-ENG T cells with the
unique ability to direct bystander T cells to CD19+ malig-
nancies. CD19-ENG T cells had potent anti-leukemia activity,
and may present a promising alternative to current
CD19-targeted immunotherapy approaches.
